NVO Jul 2024 135.000 put
| Previous close | 6.55 |
| Open | 7.05 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 135.00 |
| Expiry date | 2024-07-19 |
| Day's range | 6.55 - 7.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.29k |
BloombergOzempic Maker Novo Starts Bond Sale to Fund Factory Purchase
(Bloomberg) -- Novo Nordisk A/S is selling bonds for the first time in more than two years to fund plans to ramp up production of its blockbuster drugs.Most Read from BloombergTrump Vows ‘Day One’ Executive Order Targeting Offshore WindMacron Puts French Banks in Play With Plan to Transform EuropeTesla Rehires Some Supercharger Workers Weeks After Musk’s CutsFive Under-the-Radar Billionaires Making Vast Fortunes in Modi's IndiaBiden Adds Tariffs on Chinese Chips, Critical Minerals, EVsThe debt s
- Reuters
UPDATE 2-Wegovy users keep weight off for four years, Novo Nordisk study says
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the cost of the effective but expensive drug. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic. "We see that once the majority of the weight loss is accrued, you don't go back and start to increase in weight if you stay on the drug," he added.
- Reuters
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
